	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S0-PMC2581757	PMC2581757	11/2008	S0-PMC2581757	['ROLE of Vitamins C and e in Regulating antioxidant and pro-oxidant markers in Preeclampsia\n\nabstract\nwe compared three groups of Pregnant women: placebo with normotensive women, group a which included preeclamptics, and group b which comprised preeclamptics who were supplemented their diets with Vitamins C and e. Mda increased from 6.22\xa0±\xa02.8 (Placebo) to 8.48\xa0±\xa01.2 (a) and 8.02\xa0±\xa01.8\xa0nmol/ghb (b).']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27306', 'vitamin B6', 8, 'Vitamins C'), ('PR_000027594', 'histone H3', 8, 'Vitamins C'), ('GO_0065007', 'biological regulation', 28, 'Regulating'), ('GO_0007128', 'meiotic prophase I', 78, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 129, 'pregnant'), ('CHEBI_27300', 'vitamin D', 297, 'vitamins C'), ('CHEBI_34840', 'methyl methacrylate', 315, 'MDA'), ('CHEBI_26130', 'biological pigment', 346, 'placebo')]
S4-PMC2581757	PMC2581757	11/2008	S4-PMC2581757	['THUS, we conclude that the use of Vitamins C and e SHOULD BE CONSIDERED for the Control of certain IMPORTANT biochemical indices during the development of Preeclampsia; HOWEVER, FURTHER STUDIES ARE NEEDED to develop methods for the PREVENTION of Preeclampsia in women at high RISK.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 51), ('FUTURE_WORK', 61), ('IMPORTANT_CONSIDERATION', 61), ('IMPORTANT_CONSIDERATION', 99), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('FUTURE_WORK', 178), ('FUTURE_WORK', 186), ('SUPERFICIAL_RELATIONSHIP', 232), ('IMPORTANT_CONSIDERATION', 276)]	10	[('CHEBI_27300', 'vitamin D', 34, 'vitamins C'), ('PR_000004900', 'complement C3', 43, 'C'), ('GO_0065007', 'biological regulation', 80, 'control'), ('GO_0007128', 'meiotic prophase I', 155, 'preeclampsia'), ('GO_0007128', 'meiotic prophase I', 246, 'preeclampsia')]
S6-PMC2581757	PMC2581757	11/2008	S6-PMC2581757	['a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking Vitamins C and E supplements [1].']	[('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 76)]	2	[('GO_0007128', 'meiotic prophase I', 44, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 100, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 115, 'E')]
S10-PMC2581757	PMC2581757	11/2008	S10-PMC2581757	['the functional consequence and the POSSIBLE ROLE of the decrease in Plasma Vitamin C reserves in Preeclampsia (pe) are CONSISTENT with the fact that women who Ingested less Vitamin C than the recommended daily allowance (8.5\xa0mg) were at a 2-fold INCREASED risk of developing pe [7].']	[('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 44), ('INCOMPLETE_EVIDENCE', 119), ('IMPORTANT_CONSIDERATION', 246)]	4	[('UBERON_0001969', 'blood plasma', 68, 'plasma'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin C'), ('GO_0007128', 'meiotic prophase I', 97, 'preeclampsia'), ('GO_0007631', 'feeding behavior', 159, 'ingested'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin C')]
S14-PMC2581757	PMC2581757	11/2008	S14-PMC2581757	['in preeclampsia, an inverse CORRELATION between Vitamin E levels and Lipid peroxidation HAS BEEN FOUND [10] SUGGESTING that Vitamin E content in Plasma MAY BE used as a prognostic MARKER of the LIKELY development of Preeclampsia [11].']	[('SUPERFICIAL_RELATIONSHIP', 28), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 97), ('INCOMPLETE_EVIDENCE', 108), ('INCOMPLETE_EVIDENCE', 152), ('SUPERFICIAL_RELATIONSHIP', 180), ('PROBABLE_UNDERSTANDING', 194)]	7	[('CHEBI_27300', 'vitamin D', 48, 'vitamin E'), ('CHEBI_18059', 'lipid', 69, 'lipid'), ('GO_0006266', 'DNA ligation', 69, 'lipid'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin E'), ('UBERON_0001969', 'blood plasma', 145, 'plasma'), ('GO_0007128', 'meiotic prophase I', 216, 'preeclampsia')]
S17-PMC2581757	PMC2581757	11/2008	S17-PMC2581757	['moreover, SOME results are at VARIANCE with the PREVAILING OPINION, SINCE increased Plasma levels of Vitamin E among women with Preeclampsia as compared to those in normotensive pregnant women HAVE BEEN REPORTED [14].']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 48), ('INCOMPLETE_EVIDENCE', 59), ('PROBABLE_UNDERSTANDING', 68), ('INCOMPLETE_EVIDENCE', 193)]	8	[('UBERON_0001969', 'blood plasma', 84, 'plasma'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin E'), ('GO_0007128', 'meiotic prophase I', 128, 'preeclampsia')]
S18-PMC2581757	PMC2581757	11/2008	S18-PMC2581757	['the latter study does not SUPPORT the HYPOTHESIS of a causal RELATIONSHIP between decreased dietary Vitamin E consumption and Plasma levels and the development of Preeclampsia.']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 61)]	3	[('CHEBI_27300', 'vitamin D', 100, 'vitamin E'), ('UBERON_0001969', 'blood plasma', 126, 'plasma'), ('GO_0007128', 'meiotic prophase I', 163, 'preeclampsia')]
S170-PMC2581757	PMC2581757	11/2008	S170-PMC2581757	['from our results we INFER the positive EFFECT of Vitamins C and E on retaining sod activity during Preeclampsia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('SUPERFICIAL_RELATIONSHIP', 39)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 64, 'E'), ('GO_0007128', 'meiotic prophase I', 99, 'preeclampsia')]
S187-PMC2581757	PMC2581757	11/2008	S187-PMC2581757	['[1] HAVE REPORTED that a significant reduction in the incidence of Preeclampsia was FOUND in women AT RISK who were taking a Vitamins C and E supplements.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 84), ('IMPORTANT_CONSIDERATION', 99)]	3	[('GO_0007128', 'meiotic prophase I', 67, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 125, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E')]
S191-PMC2581757	PMC2581757	11/2008	S191-PMC2581757	['[7] HAVE REPORTED a 2-fold increased risk of developing Preeclampsia in women taking lower Vitamin C doses.']	[('INCOMPLETE_EVIDENCE', 4)]	1	[('GO_0007128', 'meiotic prophase I', 56, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin C')]
S198-PMC2581757	PMC2581757	11/2008	S198-PMC2581757	['the activities of antioxidant enzymes were also INFLUENCED by the use of Vitamins C and E. the reduction of sod activity during the development of Preeclampsia was controlled as a CONSEQUENCE of Vitamin consumption: the decrease was FOUND TO BE 14% WHEREAS it was 23% in patients who had not used Vitamins C and E. the most prominent EFFECT of the use of these Vitamins was FOUND TO BE ASSOCIATED with the activity of Glutathione reductase.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('PROBABLE_UNDERSTANDING', 180), ('ANOMALY_CURIOUS_FINDING', 233), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 249), ('SUPERFICIAL_RELATIONSHIP', 334), ('ANOMALY_CURIOUS_FINDING', 374), ('SUPERFICIAL_RELATIONSHIP', 386)]	7	[('CHEBI_27300', 'vitamin D', 73, 'vitamins C'), ('PR_000004900', 'complement C3', 82, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 88, 'E'), ('GO_0007128', 'meiotic prophase I', 147, 'preeclampsia'), ('CHEBI_33229', 'vitamin (role)', 195, 'vitamin'), ('CHEBI_27300', 'vitamin D', 297, 'vitamins C'), ('PR_000004900', 'complement C3', 306, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 312, 'E'), ('CHEBI_33277', 'gamma-tocotrienol', 361, 'vitamins'), ('CHEBI_16856', 'glutathione', 418, 'glutathione')]
S200-PMC2581757	PMC2581757	11/2008	S200-PMC2581757	['THUS, we conclude that use of Vitamins C and E DEFINITELY Controls certain IMPORTANT biochemical indices during the development of Preeclampsia, and that FURTHER STUDIES ARE NEEDED to DEVELOP STRATEGIES for the PREVENTION of Preeclampsia in women at high RISK.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 47), ('IMPORTANT_CONSIDERATION', 75), ('FUTURE_WORK', 154), ('FUTURE_WORK', 162), ('FUTURE_WORK', 184), ('FUTURE_WORK', 192), ('SUPERFICIAL_RELATIONSHIP', 211), ('IMPORTANT_CONSIDERATION', 255)]	9	[('CHEBI_27300', 'vitamin D', 30, 'vitamins C'), ('PR_000004900', 'complement C3', 39, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 45, 'E'), ('GO_0065007', 'biological regulation', 58, 'controls'), ('GO_0007128', 'meiotic prophase I', 131, 'preeclampsia'), ('GO_0007128', 'meiotic prophase I', 225, 'preeclampsia')]
S16-PMC3004407	PMC3004407	12/2010	S16-PMC3004407	['RATHER, Vitamin D is now seen as a preprohormone whose active Metabolites act not only to ensure Calcium Homeostasis and bone health [5] but also act as mediators of Immune function in general [6,7], and specific to Pregnancy, play a ROLE in Immune tolerance, Insulin resistance, and Preeclampsia [8–12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 234)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_25212', 'metabolite', 62, 'metabolites'), ('GO_0055073', 'cadmium ion homeostasis', 97, 'calcium homeostasis'), ('UBERON_0002405', 'immune system', 166, 'immune'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0002405', 'immune system', 242, 'immune'), ('PR_000045358', 'insulin family protein', 260, 'insulin'), ('GO_0007128', 'meiotic prophase I', 284, 'preeclampsia')]
S2-PMC3061267	PMC3061267	2/2011	S2-PMC3061267	['adequate Vitamin D and Calcium nutrition throughout Life MAY reduce the RISK of osteoporosis, and Calcium supplementation during Pregnancy MAY reduce Preeclampsia and low Birth weight.']	[('INCOMPLETE_EVIDENCE', 57), ('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 139)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 23, 'calcium'), ('UBERON_0000104', 'life cycle', 52, 'life'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 150, 'preeclampsia'), ('GO_0007567', 'parturition', 171, 'birth')]
S145-PMC3171895	PMC3171895	9/2011	S145-PMC3171895	['a CONSIDERABLE INTEREST exists regarding PREVENTION of Maternal and Perinatal Morbidity with Vitamins C and E. HOWEVER, the most RECENT meta-analysis of ten trials (6533 women) published in 2008 of antioxidant supplementation (including Vitamin C and e but also OTHER supplements such as Lycopene) SHOWED no difference in the relative risk (rr) of Preeclampsia (rr 0.73, 95% ci 0.51 to 1.06), Preterm Birth (before 37 weeks) (rr 1.10, 95% ci 0.99 to 1.22), sga infants (rr 0.83, 95% ci 0.62 to 1.11), or any baby death (rr 1.12, 95% ci 0.81 to 1.53) [7].']	[('ANOMALY_CURIOUS_FINDING', 2), ('ANOMALY_CURIOUS_FINDING', 15), ('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 129), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 262), ('INCOMPLETE_EVIDENCE', 298)]	8	[('GO_0007618', 'mating', 55, 'maternal ...'), ('GO_0019230', 'proprioception', 68, 'perinatal morbidity'), ('UBERON_0012101', 'perinatal stage', 68, 'perinatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin C'), ('CHEBI_15948', 'lycopene', 288, 'lycopene'), ('GO_0007128', 'meiotic prophase I', 348, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 393, 'preterm'), ('GO_0007567', 'parturition', 401, 'birth')]
S147-PMC3171895	PMC3171895	9/2011	S147-PMC3171895	['a couple of subsequent RECENT multicentre double-blinded randomised trials of a combination of Vitamin C and E [130,131] also FOUND that supplementation did not reduce the rate of Preeclampsia or Gestational hypertension and, like the Vitamins in Preeclampsia trial in 2006 [132], increased the risk of fetal loss or Perinatal death and preterm prelabour rupture of Membranes.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 126)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 109, 'E'), ('GO_0007128', 'meiotic prophase I', 180, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 196, 'gestational'), ('CHEBI_28371', 'vitamin K epoxide', 235, 'Vitamins'), ('GO_0007128', 'meiotic prophase I', 247, 'Preeclampsia'), ('GO_0036268', 'swimming', 317, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 317, 'perinatal'), ('UBERON_0000922', 'embryo', 366, 'membranes')]
S148-PMC3171895	PMC3171895	9/2011	S148-PMC3171895	['ANOTHER RECENT multicentre placebo-controlled TRIAL of Vitamin C and E in women with type-1 diabetes in Pregnancy (Dapit) also REPORTED no differences in the rates of Preeclampsia between supplemented or placebo groups [133].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 127)]	4	"[('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 69, 'E'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 115, 'DAPIT'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia')]"
S149-PMC3171895	PMC3171895	9/2011	S149-PMC3171895	['FURTHER INVESTIGATIONS are REQUIRED AS the concentrations of these Vitamins REMAIN significantly reduced in women with Preeclampsia, but in the absence OF FURTHER EVIDENCE, routine supplementation with higher dose Vitamin C and E is not RECOMMENDED AS they CAN be POTENTIALLY dangerous in high concentrations.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('IMPORTANT_CONSIDERATION', 27), ('PROBABLE_UNDERSTANDING', 36), ('INCOMPLETE_EVIDENCE', 76), ('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 155), ('FUTURE_WORK', 237), ('PROBABLE_UNDERSTANDING', 249), ('INCOMPLETE_EVIDENCE', 257), ('INCOMPLETE_EVIDENCE', 264)]	11	[('CHEBI_33277', 'gamma-tocotrienol', 67, 'vitamins'), ('GO_0007128', 'meiotic prophase I', 119, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 228, 'E')]
S224-PMC3347028	PMC3347028	3/2012	S224-PMC3347028	['it is INTERESTING that epidemiological studies involving Pregnant women with Preeclampsia—a clinical picture of inflammation and vasculitis—Vitamin D deficiency HAS BEEN IMPLICATED [152,153,154].']	[('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 161), ('SUPERFICIAL_RELATIONSHIP', 170)]	3	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 77, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D')]
S233-PMC3347028	PMC3347028	3/2012	S233-PMC3347028	['looking carefully at the INCREASING NUMBER OF epidemiological STUDIES involving women with Preeclampsia: is there a LINK with Vitamin D deficiency where PERHAPS in certain women, there is loss of the Vitamin D-mediated Suppression Of T Cells that leads to a profound inflammatory reaction REMINISCENT of graft- vs. -host disease?']	[('IMPORTANT_CONSIDERATION', 25), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 116), ('INCOMPLETE_EVIDENCE', 153), ('ANOMALY_CURIOUS_FINDING', 289), ('EXPLICIT_QUESTION', 328)]	6	[('GO_0007128', 'meiotic prophase I', 91, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('GO_0048469', 'cell maturation', 219, 'suppression of T cells'), ('CL_0000084', 'T cell', 234, 'T cells')]
S150-PMC3356951	PMC3356951	4/2012	S150-PMC3356951	['in patients with Extrarenal Production of 1,25(Oh)2D, serial monitoring of 25(Oh)D levels and Serum calcium levels during treatment with Vitamin D to prevent hypercalcemia is SUGGESTED [table 2].']	[('INCOMPLETE_EVIDENCE', 175)]	1	[('UBERON_0001691', 'external ear', 17, 'extrarenal'), ('GO_0007128', 'meiotic prophase I', 28, 'production'), ('CHEBI_82784', 'PVP38-Ag NP', 42, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('UBERON_0001977', 'blood serum', 94, 'serum'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S259-PMC3407995	PMC3407995	7/2012	S259-PMC3407995	['SEVERAL STUDIES have DEMONSTRATED an ASSOCIATION between POOR maternal Vitamin D status and SEVERE Preeclampsia that CAN result in Miscarriage [141].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 37), ('IMPORTANT_CONSIDERATION', 57), ('IMPORTANT_CONSIDERATION', 92), ('INCOMPLETE_EVIDENCE', 117)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 99, 'preeclampsia'), ('GO_0046660', 'female sex differentiation', 131, 'miscarriage')]
S289-PMC3407995	PMC3407995	7/2012	S289-PMC3407995	['Pregnancy maintenance\na cohort study of 23,423 nulliparous Pregnant women taking part in the norwegian mother and child cohort study FOUND a 27% reduction in risk of Preeclampsia in women taking Vitamin D supplements relative to those who did not take Supplements [145].']	[('INCOMPLETE_EVIDENCE', 133)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 166, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 252, 'supplements')]
S486-PMC3407995	PMC3407995	7/2012	S486-PMC3407995	['epidemiological studies have LINKED low maternal Vitamin D status to SEVERE Preeclampsia resulting in Miscarriage, risk of low Birth weight and small-for-Gestational age infants, neonatal hypocalcaemia with seizures and POSSIBLE INVOLVEMENT in the development of schizophrenia.']	[('SUPERFICIAL_RELATIONSHIP', 29), ('IMPORTANT_CONSIDERATION', 69), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 229)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 76, 'preeclampsia'), ('GO_0046660', 'female sex differentiation', 102, 'miscarriage'), ('GO_0007567', 'parturition', 127, 'birth'), ('GO_0007565', 'female pregnancy', 154, 'gestational')]
S2-PMC3471827	PMC3471827	10/2012	S2-PMC3471827	['ttp and Vitamin E are ESSENTIAL for Productive Pregnancy in rodents, but their precise physiological ROLE in Embryogenesis is UNKNOWN.']	[('IMPORTANT_CONSIDERATION', 22), ('SUPERFICIAL_RELATIONSHIP', 101), ('FULL_UNKNOWN', 126)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin E'), ('GO_0007128', 'meiotic prophase I', 36, 'productive'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('GO_0009790', 'embryo development', 109, 'embryogenesis')]
S134-PMC3552819	PMC3552819	12/2012	S134-PMC3552819	['caption (table-wrap): table 4\n\nPregnancy and newborn outcomes for Pregnant participants who received only a single dose of 70,000 iu Vitamin D at enrollment and were followed up to Deliveryn13Gestational age at Birth , weeks (by lmp)amean (±sd)38.8 (±1.8)range35.7 – 42.0 Preterm, n (%)2 (15%) Birth weightb(g)\xa0mean (±sd)c2441 (±354)range (g)1890 – 3005n/n (%) low Birth weight6/12 (50%) Delivery mode , n/n (%) cesarean sectiond8/13 (62%) sex , n (%) female5 (38%) live Birthse12/13 alive at 1 month of agef11/13\na.in a sample of 113 Deliveries at the study site (october 2009 to january 2010) for which there was a recalled first day of last Menstrual period, the mean Gestational age at Birth was ESTIMATED to be 39.7 weeks (±2.2).']	[('INCOMPLETE_EVIDENCE', 700)]	1	[('GO_0007565', 'female pregnancy', 31, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 66, 'pregnant'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0042742', 'defense response to bacterium', 181, 'deliveryN13Gestational'), ('GO_0007567', 'parturition', 211, 'birth'), ('GO_0007128', 'meiotic prophase I', 272, 'Preterm'), ('GO_0007567', 'parturition', 294, 'Birth'), ('GO_0007567', 'parturition', 365, 'Birth'), ('GO_0007586', 'digestion', 388, 'Delivery'), ('GO_0007596', 'blood coagulation', 471, 'birthse12'), ('GO_0007567', 'parturition', 535, 'deliveries'), ('GO_0007613', 'memory', 644, 'menstrual'), ('UBERON_0001347', 'white adipose tissue', 644, 'menstrual'), ('GO_0007565', 'female pregnancy', 671, 'gestational'), ('GO_0007567', 'parturition', 690, 'birth')]
S10-PMC3582478	PMC3582478	2/2013	S10-PMC3582478	['changes in Fatty Acid composition during Pregnancy quickly return to the normal range following Parturition HOWEVER, an increase in the Omega-6/3 ratio increases the risk of Ppd11,12low maternal Omega-3 Polyunsaturated Fatty Acid Intake is SUGGESTED to CONTRIBUTE to decreased maternal and fetal health, INTERACTING with the Serotonin transporter Alleles to CONTRIBUTE TO ppd.13\ndecreased Pregnancy Vitamin D ASSOCIATES with many RISK FACTORS for ppd, including Preeclampsia,14SUGGESTING that it will indirectly Modulate ppd susceptibility.']	[('ANOMALY_CURIOUS_FINDING', 108), ('INCOMPLETE_EVIDENCE', 240), ('SUPERFICIAL_RELATIONSHIP', 253), ('SUPERFICIAL_RELATIONSHIP', 304), ('SUPERFICIAL_RELATIONSHIP', 358), ('SUPERFICIAL_RELATIONSHIP', 409), ('SUPERFICIAL_RELATIONSHIP', 430), ('INCOMPLETE_EVIDENCE', 475)]	8	[('CHEBI_35366', 'fatty acid', 11, 'fatty acid'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0019230', 'proprioception', 96, 'parturition'), ('CHEBI_30823', 'oleate', 136, 'omega'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 174, 'PPD11'), ('CHEBI_79370', 'ibho#10', 195, 'omega-3'), ('GO_0033576', 'protein glycosylation in cytosol', 203, 'polyunsaturated fatty acid intake'), ('CHEBI_35366', 'fatty acid', 219, 'fatty acid'), ('CHEBI_28790', 'serotonin', 325, 'serotonin'), ('SO_0001023', 'allele', 347, 'alleles'), ('GO_0007565', 'female pregnancy', 389, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 462, 'preeclampsia'), ('GO_0065007', 'biological regulation', 512, 'modulate')]
S13-PMC3616124	PMC3616124	4/2013	S13-PMC3616124	['hp phenotype does not influence Preeclampsia RISK, or identify a subset of women who MAY BENEFIT from Vitamin C and E supplementation to prevent Preeclampsia.']	[('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 85), ('IMPORTANT_CONSIDERATION', 89)]	3	[('GO_0007128', 'meiotic prophase I', 32, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 116, 'E'), ('GO_0007128', 'meiotic prophase I', 145, 'preeclampsia')]
S173-PMC3616124	PMC3616124	4/2013	S173-PMC3616124	['THEREFORE, we EXAMINED the POTENTIAL for hp phenotype to INFLUENCE the effectiveness of Vitamin C and E in preventing Preeclampsia and SERIOUS COMPLICATIONS of pah.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 57), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 143)]	6	[('CHEBI_27300', 'vitamin D', 88, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 102, 'E'), ('GO_0007128', 'meiotic prophase I', 118, 'preeclampsia')]
S174-PMC3616124	PMC3616124	4/2013	S174-PMC3616124	['daily Vitamin C and E did not prevent Preeclampsia or SERIOUS COMPLICATIONS of pah in low risk primiparous women of any hp phenotype.']	[('IMPORTANT_CONSIDERATION', 54), ('PROBLEM_COMPLICATION', 62)]	2	[('CHEBI_27300', 'vitamin D', 6, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 20, 'E'), ('GO_0007128', 'meiotic prophase I', 38, 'preeclampsia')]
S191-PMC3616124	PMC3616124	4/2013	S191-PMC3616124	['in PARTIAL SUPPORT of this HYPOTHESIS, we OBSERVED a 3-fold increase in Preeclampsia risk in hp 2-2 hispanic women receiving Vitamin C and E. the original rct combined Vitamins C and E, an approach used in Cardiovascular disease prevention trials[47],[48],[49]that was successful in SMALL clinical trials.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 283)]	5	[('GO_0007128', 'meiotic prophase I', 72, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 139, 'E'), ('CHEBI_27300', 'vitamin D', 168, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 183, 'E'), ('UBERON_0004535', 'cardiovascular system', 206, 'cardiovascular')]
S203-PMC3616124	PMC3616124	4/2013	S203-PMC3616124	['conclusions\nIN CONTRAST TO our HYPOTHESIS, our secondary analysis of a large rct INDICATES that hp phenotype does not influence preeclampsia risk, or identify a subset of nulligravidas for whom Vitamins C and E would reduce Preeclampsia RISK in white, black or hispanic women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 81), ('IMPORTANT_CONSIDERATION', 237)]	4	[('CHEBI_27300', 'vitamin D', 194, 'vitamins C'), ('PR_000004900', 'complement C3', 203, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'E'), ('GO_0007128', 'meiotic prophase I', 224, 'preeclampsia')]
S101-PMC3659910	PMC3659910	1/2013	S101-PMC3659910	['a NEW STUDY FINDS that women who develop SEVERE Preeclampsia TEND to have lower Blood levels of Vitamin D than healthy Pregnant women raising the POSSIBILITY that the vitamin plays a ROLE in the COMPLICATION.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 41), ('PROBABLE_UNDERSTANDING', 61), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 183), ('IMPORTANT_CONSIDERATION', 195)]	7	[('GO_0007128', 'meiotic prophase I', 48, 'preeclampsia'), ('UBERON_0000178', 'blood', 80, 'blood'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnant')]
S107-PMC3659910	PMC3659910	1/2013	S107-PMC3659910	['two clinical trials SUPPORT a POTENTIAL ROLE of Vitamin D in the PREVENTION of Preeclampsia, ALTHOUGH neither of these treated with Vitamin D supplements alone.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 65), ('INCOMPLETE_EVIDENCE', 93)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 79, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
S45-PMC3702245	PMC3702245	6/2013	S45-PMC3702245	['CONSISTENT with THIS report, a systematic review and meta-analysis of seven observational studies performed between 2008 and 2011 FOUND Serum 25(Oh)D < 50 nmol/l to be ASSOCIATED with Gestational diabetes BUT with an overall lower odds ratio of 1.61 (ci 1.19–2.17).86another meta-analysis of maternal Vitamin D status and Pregnancy outcomes,87which included 24 studies up to 2012, FOUND an overall INCREASED RISK of Preeclampsia (odds ratio 2.09; ci 1.50–2.90) and Gestational diabetes (odds ratio 1.38; ci 1.12–1.70).']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 168), ('ANOMALY_CURIOUS_FINDING', 205), ('INCOMPLETE_EVIDENCE', 381), ('IMPORTANT_CONSIDERATION', 398)]	7	[('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 142, '25(OH)D'), ('GO_0007565', 'female pregnancy', 184, 'gestational'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 322, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 416, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 465, 'gestational')]
S55-PMC3809191	PMC3809191	1/2013	S55-PMC3809191	['in ONE cross-sectional STUDY, Serum 25(Oh) D levels during 24-28 weeks of Gestation were lower in gdm women than in nondiabetic Pregnant women.9in ANOTHER STUDY, maternal Serum 25 (Oh) D concentrations measured at the time of gdm screening test were significantly and inversely ASSOCIATED with fasting glucose, ALTHOUGH the ASSOCIATION of Vitamin D with gdm risk was not statistically significant.8our FINDINGS are also CONSISTENT with a study in an indian population, SHOWING no significant ASSOCIATION between 25 (Oh) D concentrations (at 30 weeks of Gestation) and gdm risk.6\ndeficiency of Vitamin D was shown to be ASSOCIATED with fetal and Brain growth deficiency and type 1 diabetes in children.13significantly reduced risk of type 1 Diabetes Mellitus Development was FOUND when high doses of Vitamin D supplementation (up to 2000 iu/d) were given during infancy in a Birth-cohort study.14\nVitamin D deficiency was also ASSOCIATED with INCREASED risk for Pregnancy complications and SERIOUS health PROBLEMS in the offspring.5,15-17higher risks of Preeclampsia and cesarean section ratios were shown in Pregnants with low levels of Vitamin D.16,17moreover supplementation of Vitamin D HAS BEEN DEMONSTRATED to decrease the RISK of Preeclampsia by 27% in a STUDY.18\n\ncaption (fig): fig.1\n\nthe correlation between Serum Vitamin D and pth levels\n\ncaption (fig): fig.2\n\nSerum Vitamin D levels in veiled and nonveiled Pregnant\n\ncaption (fig): fig.3\n\nVitamin D levels and the frequency of muscle cramps (x²=3.57, p=0.05).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 278), ('ANOMALY_CURIOUS_FINDING', 311), ('SUPERFICIAL_RELATIONSHIP', 324), ('INCOMPLETE_EVIDENCE', 402), ('INCOMPLETE_EVIDENCE', 420), ('INCOMPLETE_EVIDENCE', 469), ('SUPERFICIAL_RELATIONSHIP', 492), ('SUPERFICIAL_RELATIONSHIP', 619), ('INCOMPLETE_EVIDENCE', 774), ('SUPERFICIAL_RELATIONSHIP', 926), ('IMPORTANT_CONSIDERATION', 942), ('IMPORTANT_CONSIDERATION', 989), ('IMPORTANT_CONSIDERATION', 1004), ('INCOMPLETE_EVIDENCE', 1190), ('IMPORTANT_CONSIDERATION', 1228), ('INCOMPLETE_EVIDENCE', 1261)]	19	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_71657', 'versiconol acetate', 36, '25(OH) D'), ('PR_000008838', 'serine protease HTRA1', 36, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('GO_0007565', 'female pregnancy', 128, 'pregnant'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_71657', 'versiconol acetate', 177, '25 (OH) D'), ('PR_000009880', 'Lon protease, mitochondrial', 177, '25 ... OH ... D'), ('CHEBI_28384', 'vitamin K', 339, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 339, 'Vitamin'), ('CHEBI_71657', 'versiconol acetate', 512, '25 (OH) D'), ('GO_0007565', 'female pregnancy', 553, 'gestation'), ('CHEBI_27300', 'vitamin D', 593, 'vitamin D'), ('UBERON_0000955', 'brain', 645, 'brain'), ('GO_1903709', 'uterine gland development', 740, 'diabetes mellitus development'), ('CHEBI_27300', 'vitamin D', 799, 'vitamin D'), ('GO_0007567', 'parturition', 874, 'birth'), ('CHEBI_28384', 'vitamin K', 896, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 1053, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 1108, 'pregnants'), ('CHEBI_28384', 'vitamin K', 1137, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 1236, 'preeclampsia'), ('UBERON_0001977', 'blood serum', 1317, 'serum'), ('CHEBI_28384', 'vitamin K', 1323, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1323, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 1371, 'Serum'), ('CHEBI_28384', 'vitamin K', 1377, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1377, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1418, 'pregnant'), ('CHEBI_28384', 'vitamin K', 1450, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1450, 'Vitamin D')]
S129-PMC4034700	PMC4034700	5/2014	S129-PMC4034700	['the ROLE of oxidative stress in mediating pe pathophysiology is SUPPORTED by REPORTS of significantly decreased levels of antioxidant Vitamins C, a, e, Β-Carotene, Glutathione levels, and iron-binding capacity in the maternal circulation of women with Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 64), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 134, 'vitamins C'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 152, 'β-carotene'), ('CHEBI_16856', 'glutathione', 164, 'glutathione'), ('GO_0007128', 'meiotic prophase I', 252, 'preeclampsia')]
S137-PMC4034700	PMC4034700	5/2014	S137-PMC4034700	['HOWEVER, DESPITE encouraging in vitro DATA and cohort trials, clinical trials aimed to treat women AT RISK of Preeclampsia with Vitamins C and E (poston et al., 2006;rumbold et al., 2006) SHOWED no reduction in the incidence of the disease.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('FUTURE_WORK', 38), ('IMPORTANT_CONSIDERATION', 99), ('INCOMPLETE_EVIDENCE', 188)]	5	[('GO_0007128', 'meiotic prophase I', 110, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 128, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 143, 'E')]
S211-PMC4113768	PMC4113768	7/2014	S211-PMC4113768	['CONSEQUENTLY, AS uvb penetration Of the Skin is REQUIRED for Vitamin D Production, citizens are AT RISK of Vitamin D deficiency in winter.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 14), ('IMPORTANT_CONSIDERATION', 48), ('IMPORTANT_CONSIDERATION', 96)]	4	[('GO_0001503', 'ossification', 33, 'of ... skin'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 71, 'production'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
S187-PMC4193194	PMC4193194	10/2014	S187-PMC4193194	['the study, called combined antioxidants and Preeclampsia prediction studies (capps), had the OBJECTIVE of determining WHETHER Vitamin C and E COULD reduce the frequency of Pregnancy related hypertension.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 93), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('INCOMPLETE_EVIDENCE', 142)]	3	[('GO_0007128', 'meiotic prophase I', 44, 'Preeclampsia'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]
S190-PMC4193194	PMC4193194	10/2014	S190-PMC4193194	['ALIGNED with this FINDINGS, the cochrane collaboration initiative have CONCLUDED on its latest review on Antioxidants for preventing pe that evidence from trials reviewed does NOT SUPPORT the use of Vitamin C and E during Pregnancy for the PREVENTION of Preeclampsia and other outcomes (rumbold et al.,2008; salles et al.,2012).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176), ('SUPERFICIAL_RELATIONSHIP', 240)]	5	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 105, 'antioxidants'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 213, 'E'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 254, 'preeclampsia')]
S165-PMC4289064	PMC4289064	1/2015	S165-PMC4289064	['the wide DIFFERENCES we find among populations for Vitamin A (table 2) SUGGEST that global data on crop and Nutrient Production (e.g.,[10]) are INSUFFICIENT for predicting the EFFECTS of pollinator declines on Human health.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 71), ('PROBLEM_COMPLICATION', 144), ('SUPERFICIAL_RELATIONSHIP', 176)]	4	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('CHEBI_33284', 'nutrient', 108, 'nutrient'), ('GO_0007128', 'meiotic prophase I', 117, 'production'), ('NCBITaxon_9606', 'Homo sapiens', 210, 'human')]
S125-PMC4302429	PMC4302429	1/2015	S125-PMC4302429	['high Vitamin D3 concentrations inhibited the Production of proinflammatory cytokine Il-6 and increased production of anti-inflammatory cytokine Il-10, WHILE Ifn-Γ production in the Cns stayed unaffected\nPREVIOUS investigations REVEALED that Vitamin D plays IMPORTANT ROLES in signaling in both the Adaptive and Innate Immune Response To Viral and bacterial Infection [16,25].']	[('ANOMALY_CURIOUS_FINDING', 151), ('INCOMPLETE_EVIDENCE', 203), ('INCOMPLETE_EVIDENCE', 227), ('IMPORTANT_CONSIDERATION', 257), ('SUPERFICIAL_RELATIONSHIP', 267)]	5	[('CHEBI_33279', 'vitamin D5', 5, 'vitamin D3'), ('GO_0007128', 'meiotic prophase I', 45, 'production'), ('PR_000001470', 'interleukin-28B', 84, 'IL-6'), ('PR_000001470', 'interleukin-28B', 144, 'IL-10'), ('PR_000008920', 'interferon alpha-7', 157, 'IFN-γ'), ('UBERON_0001017', 'central nervous system', 181, 'CNS'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('GO_0051886', 'negative regulation of timing of anagen', 298, 'adaptive ...'), ('GO_0045048', 'protein insertion into ER membrane', 311, 'innate immune response to ... infection'), ('UBERON_0002405', 'immune system', 318, 'immune'), ('NCBITaxon_1', 'root', 337, 'viral')]
S139-PMC4377879	PMC4377879	3/2015	S139-PMC4377879	['high-dose supplementation with Vitamin C and Vitamin E HAS BEEN FOUND to not prevent Preeclampsia but to increase the rate of babies Born with low birthweight [59].']	[('INCOMPLETE_EVIDENCE', 55)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin E'), ('GO_0007128', 'meiotic prophase I', 85, 'preeclampsia'), ('GO_0007567', 'parturition', 133, 'born')]
S7-PMC4380518	PMC4380518	9/2014	S7-PMC4380518	['introduction\nPerinatal health outcomes VARY dramatically by race in the united states.1african american women develop Preeclampsia more OFTEN than their white counterparts2and are more LIKELY to develop preterm labor.3the result is that black infants are 60% more LIKELY BE preterm and four times more LIKELY to die due to prematurity than white infants.1BECAUSE of less efficient Vitamin D Synthesis in the skin of darker Pigmented Individuals, african americans are at higher RISK than white americans of Vitamin D deficiency.4,5black women are also more LIKELY than white women to be overweight or obese6which is of CONCERN BECAUSE obesity is another RISK FACTOR for Vitamin D deficiency5,7and poor Perinatal outcomes.8in OBSERVATIONAL studies, 25-Hydroxyvitamin D (25[Oh]D) levels HAVE BEEN SHOWN to be ASSOCIATED with higher risk of several adverse Perinatal outcomes including Gestational diabetes9,10, preeclampsia,11preterm Birth12And small-for-Gestational age status.13,14,15,16,17BECAUSE of the PAUCITY of Vitamin D trial data with respect to Perinatal outcomes, WHETHER DIFFERENCES in Vitamin D status during Pregnancy explains or partially explains Perinatal DISPARITIES is PLAUSIBLE18but REMAINS UNKNOWN.']	[('DIFFICULT_TASK', 39), ('PROBABLE_UNDERSTANDING', 136), ('PROBABLE_UNDERSTANDING', 185), ('PROBABLE_UNDERSTANDING', 264), ('PROBABLE_UNDERSTANDING', 302), ('PROBABLE_UNDERSTANDING', 355), ('IMPORTANT_CONSIDERATION', 478), ('PROBABLE_UNDERSTANDING', 557), ('PROBLEM_COMPLICATION', 619), ('PROBABLE_UNDERSTANDING', 627), ('SUPERFICIAL_RELATIONSHIP', 654), ('INCOMPLETE_EVIDENCE', 725), ('INCOMPLETE_EVIDENCE', 785), ('SUPERFICIAL_RELATIONSHIP', 807), ('PROBABLE_UNDERSTANDING', 990), ('INCOMPLETE_EVIDENCE', 1005), ('EXPLICIT_QUESTION', 1073), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1081), ('IMPORTANT_CONSIDERATION', 1171), ('INCOMPLETE_EVIDENCE', 1186), ('FULL_UNKNOWN', 1201)]	21	[('GO_0036268', 'swimming', 13, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 13, 'Perinatal'), ('GO_0007128', 'meiotic prophase I', 118, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 381, 'vitamin D synthesis'), ('CHEBI_26130', 'biological pigment', 423, 'pigmented'), ('NCBITaxon_1', 'root', 433, 'individuals'), ('CHEBI_27300', 'vitamin D', 507, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 670, 'vitamin D'), ('GO_0036268', 'swimming', 702, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 702, 'perinatal'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 748, '25-hydroxyvitamin D'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 769, '25[OH]D'), ('GO_0036268', 'swimming', 854, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 854, 'perinatal'), ('GO_0007565', 'female pregnancy', 883, 'gestational'), ('GO_0007594', 'puparial adhesion', 932, 'birth12and'), ('GO_0007565', 'female pregnancy', 953, 'gestational'), ('CHEBI_27300', 'vitamin D', 1016, 'vitamin D'), ('GO_0036268', 'swimming', 1053, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1053, 'perinatal'), ('CHEBI_27300', 'vitamin D', 1096, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1120, 'pregnancy'), ('GO_0036268', 'swimming', 1161, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1161, 'perinatal')]
S24-PMC4405493	PMC4405493	4/2015	S24-PMC4405493	['THUS, we SOUGHT TO DETERMINE IF Vitamin D deficiency in the first trimester of nulliparous patients is ASSOCIATED with clinical outcomes MOST ASSOCIATED with SIGNIFICANT maternal and fetal morbidity and mortality: Preeclampsia, Gestational diabetes, Preterm Delivery, spontaneous abortion, and growth restriction.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 29), ('SUPERFICIAL_RELATIONSHIP', 103), ('PROBABLE_UNDERSTANDING', 137), ('SUPERFICIAL_RELATIONSHIP', 142), ('IMPORTANT_CONSIDERATION', 158)]	8	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 214, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 228, 'gestational'), ('GO_0007565', 'female pregnancy', 250, 'preterm'), ('GO_0007567', 'parturition', 258, 'delivery')]
S77-PMC4405493	PMC4405493	4/2015	S77-PMC4405493	['mean Gestational age of recruitment and Vitamin D Plasma measurement was 62.2 ± 29.7 days (8.9 ± 4.2 weeks).a Pregnancy was considered COMPLICATED if the patient was diagnosed with any of the following adverse Pregnancy outcomes: Preeclampsia, Gestational diabetes, spontaneous Preterm Delivery, Intrauterine growth restriction, or spontaneous Abortion (table 1).']	[('DIFFICULT_TASK', 135)]	1	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 50, 'plasma'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 210, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 230, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('GO_0007565', 'female pregnancy', 278, 'preterm'), ('GO_0007567', 'parturition', 286, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 296, 'intrauterine'), ('GO_0007569', 'cell aging', 344, 'abortion')]
S105-PMC4405493	PMC4405493	4/2015	S105-PMC4405493	['BECAUSE there were TOO few patient in the category of Vitamin D deficient (<20ng/ml [50nmol/l]) for meaningful statistical analysis, patients categorized as either Vitamin D insufficient or deficient were combined into one category (insufficient/deficient, <30ng/ml [75nmol/l]) for subsequent statistical analysis (table 5).10.1371/journal.pone.0123763.t004\n\ncaption (table-wrap): table 4\ndistribution of clinical outcomes in women categorized as Vitamin D deficient, insufficient, or sufficient.Vitamin D categoryno complications n (% of 176)all complications n (% of 59)Preeclampsia n (% of 19)spontaneous Preterm Delivery n (% of 10)iugr n (% of 9)gdm n (% of 5)spontaneous fetal loss n (% of 16) deficient (<20 ng/ml) 18 (10)6 (10)2 (11)1 (10)1 (11)0 (0)2 (13) (n = 24)insufficient (21–29 ng/ml) 105 (60)36 (61)10 (53)6 (60)7 (78)3 (60)10 (63) (n = 141)sufficient (>30 ng/ml) 53 (30)17 (29)7 (37)3 (30)1 (11)2 (40)4 (25) (n = 70)\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.10.1371/journal.pone.0123763.t005\n\ncaption (table-wrap): table 5\nlogistic regression analysis of clinical outcomes in women categorized as Vitamin D sufficient compared to Vitamin D insufficient or deficient women.Vitamin D sufficient (≥30 ng/ml)Vitamin D insufficient or deficient (<30 ng/ml)n (% of 70)n (% of 165)adjusted**or (95% ci)* no complications 53 (75.7)123 (74.5)- all complications 17 (24.2)42 (25.5)1.01 (0.947–1.164) Preeclampsia 7 (10)12 (7.2)1.36 (0.48–3.88) spontaneous Preterm Delivery 3 (4.3)7 (4.2)0.78 (0.17–3.55) iugr 1 (1.4)8 (4.8)0.33 (0.38–2.83) gdm 2 (2.9)3 (1.8)2.60 (0.28–27.24) spontaneous abortion 4 (5.7)12 (7.2)0.65 (0.18–2.28)\n*, note: none of the differences were p<0.05 by logistic regression (chi-square analysis)\n**, adjusted for bmi, season, ethnicity, and tobacco use\nor, odds ratio\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.']	[('PROBLEM_COMPLICATION', 0), ('PROBLEM_COMPLICATION', 19)]	2	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 447, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 447, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 496, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 496, 'Vitamin D'), ('GO_0007128', 'meiotic prophase I', 572, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 608, 'Preterm'), ('GO_0007567', 'parturition', 616, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 940, 'intrauterine'), ('GO_0007565', 'female pregnancy', 978, 'gestational'), ('CHEBI_27300', 'vitamin D', 1147, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1222, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 1254, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1254, 'Vitamin D'), ('GO_0007128', 'meiotic prophase I', 1440, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 1496, 'Preterm'), ('GO_0007567', 'parturition', 1504, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 1837, 'intrauterine'), ('GO_0007565', 'female pregnancy', 1875, 'gestational')]
S147-PMC4405493	PMC4405493	4/2015	S147-PMC4405493	['the ROLE Vitamin D plays in adverse clinical outcomes such as Preeclampsia, Gestational diabetes, Preterm Labor, growth restriction, and spontaneous Abortion is SPECULATIVE, but MAY INVOLVE Vitamin D’s Regulation Of Placental Trophoblast Invasion and Angiogenesis, in addition to its anti-inflammatory properties [5].']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 182), ('SUPERFICIAL_RELATIONSHIP', 202)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 62, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 76, 'gestational'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 98, 'preterm labor'), ('GO_0007569', 'cell aging', 149, 'abortion'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('GO_1900101', 'regulation of endoplasmic reticulum unfolded protein response', 202, 'regulation of ... invasion ...'), ('UBERON_0001987', 'placenta', 216, 'placental'), ('UBERON_0000088', 'trophoblast', 226, 'trophoblast'), ('GO_0001525', 'angiogenesis', 251, 'angiogenesis')]
S80-PMC4684854	PMC4684854	12/2015	S80-PMC4684854	['the authors of this study also NOTED that women with lower Vitamin D levels had higher degrees of various Autoantibodies including Antiphospholipid Antibody [50], a clinical state that HAS BEEN ASSOCIATED with fetal death, recurrent early Miscarriage, Preeclampsia, and Placental insufficiency [51].']	[('ANOMALY_CURIOUS_FINDING', 31), ('INCOMPLETE_EVIDENCE', 185), ('SUPERFICIAL_RELATIONSHIP', 194)]	3	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0044308', 'axonal spine', 106, 'autoantibodies'), ('CHEBI_16240', 'hydrogen peroxide', 131, 'antiphospholipid'), ('GO_0042571', 'immunoglobulin complex, circulating', 148, 'antibody'), ('GO_0046660', 'female sex differentiation', 239, 'miscarriage'), ('GO_0007128', 'meiotic prophase I', 252, 'preeclampsia'), ('UBERON_0001987', 'placenta', 270, 'placental')]
S85-PMC4684854	PMC4684854	12/2015	S85-PMC4684854	['NUMEROUS STUDIES have also CORRELATED low levels of Vitamin D with the development of Preeclampsia [52,53,55,56], PERHAPS through Immune mechanisms involving Antiphospholipid Antibody [51], and/or inflammatory mechanisms involving cytokines [56].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 27), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 86, 'preeclampsia'), ('UBERON_0002405', 'immune system', 130, 'immune'), ('CHEBI_16240', 'hydrogen peroxide', 158, 'antiphospholipid'), ('GO_0042571', 'immunoglobulin complex, circulating', 175, 'antibody')]
S95-PMC4684854	PMC4684854	12/2015	S95-PMC4684854	['another systematic review and meta-analysis published in the british medical journal also LINKED Vitamin D insufficiency with an INCREASED RISK of Gestational diabetes, Preeclampsia, and small for Gestational age infants [65].']	[('SUPERFICIAL_RELATIONSHIP', 90), ('IMPORTANT_CONSIDERATION', 129)]	2	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'gestational'), ('GO_0007128', 'meiotic prophase I', 169, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 197, 'gestational')]
S36-PMC4764019	PMC4764019	1/2016	S36-PMC4764019	['pregnancy complications\none of the most STRIKING and SURPRISING findings to emerge from the finnish Birth cohort study DESCRIBED PREVIOUSLY was the fact that 20+ years after their infancy exposure to Vitamin D, women in the cohort who, as Adults, became Pregnant exhibited an APPROXIMATE 50% reduction in risk of Preeclampsia in their own first Pregnancies,8once again, relative to women who had not received the then RECOMMENDED 2000 iu/d of Vitamin D in infancy.']	[('ANOMALY_CURIOUS_FINDING', 40), ('ANOMALY_CURIOUS_FINDING', 53), ('INCOMPLETE_EVIDENCE', 119), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 276), ('FUTURE_WORK', 418)]	6	[('GO_0007567', 'parturition', 100, 'birth'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0007023', 'adult organism', 239, 'adults'), ('GO_0007565', 'female pregnancy', 254, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 313, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 345, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D')]
S54-PMC4764019	PMC4764019	1/2016	S54-PMC4764019	['these Genes cover a broad range of functions ranging from cell-to-Cell adhesion, to Macrophage Production of defensins in response to mycobacterial infection, to Intestinal calcium absorption, and many others.13in ESSENTIALLY all such actions, Vitamin D, in its active form as 1,25(Oh)2D3, functions as a part of the molecular apparatus opening the Genome, permitting Expression of the Genes concerned.']	[('PROBABLE_UNDERSTANDING', 214)]	1	[('SO_0000704', 'gene', 6, 'genes'), ('GO_1901646', 'negative regulation of synoviocyte proliferation', 62, '- ...'), ('GO_0007049', 'cell cycle', 66, 'cell'), ('CL_0000235', 'macrophage', 84, 'macrophage'), ('GO_0007128', 'meiotic prophase I', 95, 'production'), ('UBERON_0000160', 'intestine', 162, 'intestinal'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin D'), ('CHEBI_37958', 'dye', 277, '1,'), ('CHEBI_73394', 'Ala-Ser', 279, '25(OH)2D3'), ('SO_0001026', 'genome', 349, 'genome'), ('GO_0010467', 'gene expression', 368, 'expression'), ('SO_0000704', 'gene', 386, 'genes')]
S0-PMC4770602	PMC4770602	1/2016	S0-PMC4770602	['EFFECT of Vitamin D supplementation in the reduce RISK of Preeclampsia in nulliparous women\n\nabstract\n\nbackground:\nthe exact ROLE of Vitamin D in the development and severity of Preeclampsia is STILL UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('IMPORTANT_CONSIDERATION', 50), ('SUPERFICIAL_RELATIONSHIP', 125), ('FULL_UNKNOWN', 194)]	4	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 58, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 178, 'preeclampsia')]
S1-PMC4770602	PMC4770602	1/2016	S1-PMC4770602	['the AIM of the PRESENT STUDY was TO INVESTIGATE the ASSOCIATION between Vitamin D supplement and Preeclampsia in Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 52)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 97, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S16-PMC4770602	PMC4770602	1/2016	S16-PMC4770602	['[5] and an ASSOCIATION between low maternal Vitamin D and early-onset, SEVERE Preeclampsia is RECENTLY REPORTED.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('IMPORTANT_CONSIDERATION', 71), ('INCOMPLETE_EVIDENCE', 94), ('INCOMPLETE_EVIDENCE', 103)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 78, 'preeclampsia')]
S18-PMC4770602	PMC4770602	1/2016	S18-PMC4770602	['[5] another data SUGGESTED with ONLY a 10ng/ml increase in maternal Vitamin D a POSSIBLE reduction of the RISK of Preeclampsia.']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 80), ('IMPORTANT_CONSIDERATION', 106)]	4	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 114, 'preeclampsia')]
S19-PMC4770602	PMC4770602	1/2016	S19-PMC4770602	['[9] also, ASSOCIATION between Vitamin D deficiency and preeclampsia is REPORTED in a population based study on 23,423 women, which authors FOUND that a 27 percent reduction in the risk for Preeclampsia was ASSOCIATED with Vitamin D intake of 15-20 micrograms per day relative to less than 5 micrograms per day.']	[('SUPERFICIAL_RELATIONSHIP', 10), ('INCOMPLETE_EVIDENCE', 71), ('INCOMPLETE_EVIDENCE', 139), ('SUPERFICIAL_RELATIONSHIP', 206)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 189, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D')]
S23-PMC4770602	PMC4770602	1/2016	S23-PMC4770602	['[518]\nbased ON the ROLE of maternal Vitamin D deficiency, AS a POTENTIAL in DEPENDENT RISK FACTOR for Preeclampsia, Vitamin D supplementation in early Pregnancy REMAINS a POSSIBLE intervention and POSSIBLE improved Pregnancy outcomes through PREVENTION or delay of Preeclampsia.']	[('ANOMALY_CURIOUS_FINDING', 12), ('ANOMALY_CURIOUS_FINDING', 12), ('SUPERFICIAL_RELATIONSHIP', 19), ('PROBABLE_UNDERSTANDING', 58), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 76), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 197), ('SUPERFICIAL_RELATIONSHIP', 242)]	11	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 102, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 265, 'preeclampsia')]
S26-PMC4770602	PMC4770602	1/2016	S26-PMC4770602	['THUS, THIS STUDY was AIMED TO EXAMINE the IMPACT of Vitamin D supplementation in reduction of RISK of Preeclampsia in nulliparous women in a randomized controlled trial.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 94)]	6	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 102, 'preeclampsia')]
S59-PMC4770602	PMC4770602	1/2016	S59-PMC4770602	['[19] in the PRESENT STUDY, we ASSESSED the EFFECT of Vitamin D supplementation in reduction of risk of Preeclampsia in nulliparous women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('SUPERFICIAL_RELATIONSHIP', 43)]	3	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 103, 'preeclampsia')]
S60-PMC4770602	PMC4770602	1/2016	S60-PMC4770602	['our results SHOWED that the frequency of Preeclampsia in case group, who received Vitamin D supplementation, was lower than control group but this difference between case and control groups was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('GO_0007128', 'meiotic prophase I', 41, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S63-PMC4770602	PMC4770602	1/2016	S63-PMC4770602	['Preeclampsia is one of the LEADING CAUSES of Maternal and Perinatal Morbidity and mortality which, Vitamin D HAS BEEN HYPOTHESIZED to INFLUENCE Preeclampsia RISK.']	[('IMPORTANT_CONSIDERATION', 27), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 134), ('IMPORTANT_CONSIDERATION', 157)]	5	[('GO_0007128', 'meiotic prophase I', 0, 'Preeclampsia'), ('GO_0007618', 'mating', 45, 'maternal ...'), ('GO_0019230', 'proprioception', 58, 'perinatal morbidity'), ('UBERON_0012101', 'perinatal stage', 58, 'perinatal'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 144, 'preeclampsia')]
S64-PMC4770602	PMC4770602	1/2016	S64-PMC4770602	['[3] in the norwegian mother and child cohort study, the ASSOCIATION between Intake of Vitamin D during Pregnancy and the risk of Preeclampsia in 23,423 Nulliparous Pregnant women was ESTIMATED and authors OBSERVED 27% reduction in risk of Preeclampsia after Vitamin D supplementation in these women.']	[('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 205)]	3	[('GO_0007631', 'feeding behavior', 76, 'intake'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 129, 'preeclampsia'), ('GO_0046662', 'regulation of oviposition', 152, 'nulliparous'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 239, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S65-PMC4770602	PMC4770602	1/2016	S65-PMC4770602	"[""[8] investigators in ANOTHER cohort STUDY REPORTED that the risk of Preeclampsia in the female offspring's first Pregnancy reduced after regular supplementation with Vitamin D in the first year of Life.""]"	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007128', 'meiotic prophase I', 68, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('UBERON_0000104', 'life cycle', 197, 'life')]
S66-PMC4770602	PMC4770602	1/2016	S66-PMC4770602	['[20] also, ROLE of Vitamin D in the PREVENTION of Preeclampsia is SUPPORTED by two clinical TRIALS, HOWEVER, in one of these STUDIES as an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil provided at 20 week Gestation reduced the odds of Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 66), ('FUTURE_WORK', 92), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('INCOMPLETE_EVIDENCE', 125)]	6	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 50, 'preeclampsia'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002107', 'liver', 226, 'liver'), ('GO_0007565', 'female pregnancy', 256, 'gestation'), ('GO_0007128', 'meiotic prophase I', 286, 'preeclampsia')]
S67-PMC4770602	PMC4770602	1/2016	S67-PMC4770602	['[21] in other study,400 women at 20-24 week Gestation randomized to Vitamin D and Calcium supplements or no treatment, results of this study SHOWS that in the treated group reduction occurred in the incidence of Preeclampsia compared with the untreated group THOUGH this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 141), ('ANOMALY_CURIOUS_FINDING', 259)]	2	[('GO_0007565', 'female pregnancy', 44, 'gestation'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium'), ('GO_0007128', 'meiotic prophase I', 212, 'preeclampsia')]
S76-PMC4770602	PMC4770602	1/2016	S76-PMC4770602	['level of calcium in studied women was an IMPORTANT unmeasured covariate in OUR STUDY, WHEREAS, low calcium intake MAY BE ASSOCIATED with Vitamin D deficiency and MAY be a RISK FACTOR for Preeclampsia.']	[('IMPORTANT_CONSIDERATION', 41), ('QUESTION_ANSWERED_BY_THIS_WORK', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 121), ('INCOMPLETE_EVIDENCE', 162), ('SUPERFICIAL_RELATIONSHIP', 171)]	7	[('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 187, 'preeclampsia')]
S78-PMC4770602	PMC4770602	1/2016	S78-PMC4770602	['THEREFORE, ADDITIONAL well-designed, prospective, randomized TRIALS of supplementation with good sample size that control for dietary exposure will BE NECESSARY to determine a POTENTIAL ROLE for Vitamin D in the PREVENTION of Preeclampsia.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 11), ('FUTURE_WORK', 148), ('INCOMPLETE_EVIDENCE', 176), ('SUPERFICIAL_RELATIONSHIP', 186), ('SUPERFICIAL_RELATIONSHIP', 212)]	6	[('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 226, 'preeclampsia')]
S79-PMC4770602	PMC4770602	1/2016	S79-PMC4770602	['in CONCLUSION, results of the PRESENT STUDY DEMONSTRATED that Vitamin D supplementation during the third Trimester of Pregnancy; reduce the RISK of Preeclampsia HOWEVER, this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 161)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 105, 'trimester'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 148, 'preeclampsia')]
S80-PMC4770602	PMC4770602	1/2016	S80-PMC4770602	['and FURTHER TRIALS ARE NEEDED to FURTHER CLARIFY the EFFECT of calcium supplementation, Vitamin D supplementation, or both on reduce the incidence of Preeclampsia.']	[('FUTURE_WORK', 4), ('FUTURE_WORK', 12), ('FUTURE_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 53)]	4	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 150, 'preeclampsia')]
S23-PMC4785305	PMC4785305	3/2016	S23-PMC4785305	['maternal Vitamin D status during Pregnancy\nvitamin D deficiency during Pregnancy is PREVALENT worldwide, ESPECIALLY in developing countries.8in a systematic review of 18 studies conducted in western countries during the first Trimester, white caucasian Pregnant women were found to have a mean 25(Oh)D level between 29 and 73\u2005nmol/l.9mean 25(Oh)D levels were lower in non-caucasian Pregnant women, ranging between 15.2 and 43\u2005nmol/l.9in addition to ethnicity, higher latitude was a significant predisposing FACTOR for hypovitaminosis d.9similarly, in non-western countries, more than half of the Pregnant women who were beyond their first trimester had 25(Oh)D levels below 75\u2005nmol/l; these include countries such as india,10kuwait,11pakistan12and turkey.13even lower levels (<25\u2005nmol/l) HAVE BEEN REPORTED at Delivery in saudi arabia, iran and the united arab emirates.14furthermore, immigrant women were at PARTICULAR RISK.1516an OBSERVATIONAL study from the netherlands SHOWED significantly lower 25(Oh)D levels during the first Trimester in immigrant Pregnant women (turkish, moroccan and others), compared to western participants.17\n\nASSOCIATION between maternal Vitamin D status and maternal adverse outcomes\nVitamin D insufficiency during Pregnancy is ASSOCIATED with adverse maternal outcomes such as increased risk of Gestational diabetes mellitus (gdm), preeclampsia, caesarean-section Delivery and bacterial vaginosis.18in a recent meta-analysis of observational studies, the risk of gdm was FOUND TO BE increased by 40–84% in Pregnant women with low 25(Oh)D levels, defined as <50\u2005nmol/l or <75\u2005nmol/l, DEPENDING ON the studies.19–21while Preeclampsia risk was significantly increased in Vitamin D insufficient women,22c-section rates were INCONSISTENTLY AFFECTED by Vitamin D status.23HOWEVER, THESE FINDINGS REMAIN LIMITED by the inherent BIASES of OBSERVATIONAL studies, INCONSISTENT adjustment for CONFOUNDERS, in addition to the wide HETEROGENEITY in Vitamin D assays and Vitamin D cut-offs definition.']	[('IMPORTANT_CONSIDERATION', 84), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 507), ('INCOMPLETE_EVIDENCE', 788), ('IMPORTANT_CONSIDERATION', 909), ('INCOMPLETE_EVIDENCE', 932), ('INCOMPLETE_EVIDENCE', 973), ('SUPERFICIAL_RELATIONSHIP', 1139), ('SUPERFICIAL_RELATIONSHIP', 1259), ('ANOMALY_CURIOUS_FINDING', 1503), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1752), ('SUPERFICIAL_RELATIONSHIP', 1767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1796), ('INCOMPLETE_EVIDENCE', 1807), ('INCOMPLETE_EVIDENCE', 1822), ('INCOMPLETE_EVIDENCE', 1829), ('PROBLEM_COMPLICATION', 1853), ('INCOMPLETE_EVIDENCE', 1863), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1886), ('PROBLEM_COMPLICATION', 1914), ('DIFFICULT_TASK', 1951)]	22	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 226, 'trimester'), ('GO_0007565', 'female pregnancy', 253, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 294, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 294, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 345, 'D'), ('GO_0007565', 'female pregnancy', 382, 'pregnant'), ('GO_0007565', 'female pregnancy', 596, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 653, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 653, '25(OH)D'), ('GO_0007567', 'parturition', 810, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 1000, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1000, '25(OH)D'), ('GO_0009294', 'DNA mediated transformation', 1032, 'trimester'), ('GO_0007565', 'female pregnancy', 1055, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1168, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1215, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1246, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1327, 'gestational'), ('GO_0007567', 'parturition', 1396, 'delivery'), ('GO_0007565', 'female pregnancy', 1538, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 1562, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 1651, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 1700, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1779, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1968, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D')]
S33-PMC4785305	PMC4785305	3/2016	S33-PMC4785305	['in these trials, DIFFERENT doses of Vitamin D, reaching up to 7000\u2005iu daily, are being administered, and the outcomes to be assessed include neonatal weight and length, childhood asthma, maternal bone Mineral density, maternal adverse outcomes, including Preeclampsia and Preterm labour, and neonatal adverse outcomes, such as sga.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 17)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_46662', 'mineral', 201, 'mineral'), ('GO_0007128', 'meiotic prophase I', 255, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 272, 'preterm')]
S12-PMC4811441	PMC4811441	3/2016	S12-PMC4811441	['in conclusion, an increase in 25(Oh)D concentration during Pregnancy of at LEAST 30 nmol/l, REGARDLESS OF Vitamin D status in t1, was ASSOCIATED with a lower odds ratio for Preeclampsia.']	[('PROBABLE_UNDERSTANDING', 75), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 173, 'preeclampsia')]
S92-PMC4903143	PMC4903143	5/2016	S92-PMC4903143	['THE literature has discussed that Vitamin D insufficiency MAY BE ASSOCIATED with first Trimester Pregnancy loss [85,86], Gestational diabetes [103,104], Preeclampsia [89,105], Preterm Birth [92,93], higher rates of primary and emergency caesarean Delivery [94,106], small for Gestational age infants [95], and maternal Postpartum depression [96].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 58), ('SUPERFICIAL_RELATIONSHIP', 65)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 87, 'trimester'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('GO_0007565', 'female pregnancy', 121, 'gestational'), ('GO_0007128', 'meiotic prophase I', 153, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 176, 'preterm birth'), ('GO_0007567', 'parturition', 247, 'delivery'), ('GO_0007565', 'female pregnancy', 276, 'gestational'), ('GO_0007565', 'female pregnancy', 319, 'postpartum')]
S109-PMC4934634	PMC4934634	11/2015	S109-PMC4934634	['Gestational diabetes\nthe IMPACT of Vitamin D on vascular health and Glucose Control CAN LIKEWISE TRANSLATE to adverse EFFECTS of Vitamin D deficiency on Pregnancy outcomes including an INCREASED risk for Gestational diabetes and Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 88), ('SUPERFICIAL_RELATIONSHIP', 97), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 185)]	6	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_28384', 'vitamin K', 35, 'Vitamin D'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0046323', 'glucose import', 68, 'glucose control'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'gestational'), ('GO_0007128', 'meiotic prophase I', 229, 'preeclampsia')]
S142-PMC4934634	PMC4934634	11/2015	S142-PMC4934634	['it SHOULD BE NOTED that OTHER STUDIES have FAILED TO CONFIRM OBSERVATIONS that lower 25(Oh)D status is ASSOCIATED with the occurrence of Preeclampsia, and it is STILL UNCLEAR WHETHER suboptimal Vitamin D status is a cause, OR an EFFECT, of preeclampsia [55,56].']	[('IMPORTANT_CONSIDERATION', 3), ('ANOMALY_CURIOUS_FINDING', 10), ('ANOMALY_CURIOUS_FINDING', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('INCOMPLETE_EVIDENCE', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 43), ('ANOMALY_CURIOUS_FINDING', 43), ('DIFFICULT_TASK', 43), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 61), ('SUPERFICIAL_RELATIONSHIP', 103), ('FULL_UNKNOWN', 161), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 175), ('SUPERFICIAL_RELATIONSHIP', 229)]	14	[('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 137, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
S143-PMC4934634	PMC4934634	11/2015	S143-PMC4934634	['anti-inflammatory and Immune modulating properties of Vitamin D are POSTULATED to CONTRIBUTE to the protective mechanism against Preeclampsia.']	[('INCOMPLETE_EVIDENCE', 68), ('SUPERFICIAL_RELATIONSHIP', 82)]	2	[('UBERON_0002405', 'immune system', 22, 'immune'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 129, 'preeclampsia')]
S145-PMC4934634	PMC4934634	11/2015	S145-PMC4934634	[', INVESTIGATED the ASSOCIATION of circulating maternal 1,25(Oh)2D levels on Preeclampsia and the EFFECT of Vitamin D supplementation on Placental Cytokine Production in Rats [57].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 2), ('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 97)]	3	[('CHEBI_82784', 'PVP38-Ag NP', 55, '1,25(OH)2D'), ('GO_0007128', 'meiotic prophase I', 76, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001987', 'placenta', 136, 'placental'), ('GO_0001814', 'negative regulation of antibody-dependent cellular cytotoxicity', 146, 'cytokine production'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 169, 'rats')]
S164-PMC4934634	PMC4934634	11/2015	S164-PMC4934634	['THUS, it is NOT SURPRISING that this study FOUND no effect of the Vitamin D supplementation on incidences of Preterm Birth, Preeclampsia, or small for Gestation age SINCE 23% of participants had persistent Serum 25(Oh)D below 10 ng/ml which IS CONSIDERED Vitamin D deficiency status by both the iom and endocrine society (table 1).']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 165), ('INCOMPLETE_EVIDENCE', 241)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'preterm birth'), ('GO_0007128', 'meiotic prophase I', 124, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S171-PMC4934634	PMC4934634	11/2015	S171-PMC4934634	['Vitamin D supplementation is a low cost intervention strategy and ADDITIONAL clinical TRIALS powered to determine the EFFECTS of Vitamin D on Preeclampsia PREVENTION and treatment ARE clearly WARRANTED.']	[('FUTURE_WORK', 66), ('SUPERFICIAL_RELATIONSHIP', 118), ('SUPERFICIAL_RELATIONSHIP', 155), ('FUTURE_WORK', 180)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 142, 'preeclampsia')]
S27-PMC5014971	PMC5014971	8/2016	S27-PMC5014971	['low to moderate quality evidence exists for a PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy for a number of Pregnancy outcomes, including Preeclampsia, being small for Gestational age, and Preterm labor [20].']	[('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 156, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 186, 'gestational'), ('GO_0007565', 'female pregnancy', 207, 'preterm')]
S85-PMC5028238	PMC5028238	10/2016	S85-PMC5028238	['this HAS BEEN used TO EXPLAIN WHY northern populations have a higher prevalence of slos.11\ncarriers also are HYPOTHESIZED to have a Reproductive advantage because of the reduced fetal death due to Rachitic Cephalopelvic disproportion.11,35this is again RELATED to increased Vitamin D Production causing improved bone formation.']	[('INCOMPLETE_EVIDENCE', 5), ('QUESTION_ANSWERED_BY_THIS_WORK', 19), ('PROBABLE_UNDERSTANDING', 22), ('EXPLICIT_QUESTION', 30), ('INCOMPLETE_EVIDENCE', 109), ('SUPERFICIAL_RELATIONSHIP', 253)]	6	"[('GO_0000003', 'reproduction', 132, 'reproductive'), ('UBERON_0001286', ""Bowman's space"", 197, 'rachitic cephalopelvic'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 284, 'production')]"
S18-PMC5084041	PMC5084041	10/2016	S18-PMC5084041	['POOR maternal Vitamin D status HAS also BEEN ASSOCIATED with Pregnancy COMPLICATIONS such as Preeclampsia [3], premature Birth [4] and infants Born small for Gestational age [5].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 31), ('SUPERFICIAL_RELATIONSHIP', 45), ('PROBLEM_COMPLICATION', 71)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 93, 'preeclampsia'), ('GO_0007567', 'parturition', 121, 'birth'), ('GO_0007567', 'parturition', 143, 'born'), ('GO_0007565', 'female pregnancy', 158, 'gestational')]
S37-PMC5084041	PMC5084041	10/2016	S37-PMC5084041	['materials and methods\nthe gravid study was DESIGNED TO INVESTIGATE the ASSOCIATION of Vitamin D status during Pregnancy with Preeclampsia and Pregnancy-induced hypertension.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 43), ('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 125, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]
S100-PMC5085625	PMC5085625	9/2016	S100-PMC5085625	['both a RECENT meta-analysis and several OBSERVATIONAL studies SHOWED a significant ASSOCIATION between Vitamin D deficiency and INCREASED RISK for Preeclampsia [39,40,41].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 40), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 83), ('IMPORTANT_CONSIDERATION', 128)]	5	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 147, 'preeclampsia')]
S105-PMC5085625	PMC5085625	9/2016	S105-PMC5085625	['SOME EVIDENCE SUGGESTS that Preeclampsia MAY BE ASSOCIATED with a decrease in Placental and fetal concentrations of Vitamin D, and Placental dysfunction plays an IMPORTANT ROLE in the pathogenesis of pe [44].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 48), ('IMPORTANT_CONSIDERATION', 162), ('SUPERFICIAL_RELATIONSHIP', 172)]	6	[('GO_0007128', 'meiotic prophase I', 28, 'preeclampsia'), ('UBERON_0001987', 'placenta', 78, 'placental'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('UBERON_0001987', 'placenta', 131, 'placental')]
S169-PMC5085625	PMC5085625	9/2016	S169-PMC5085625	['conclusions\nin CONCLUSION, both the results of PREVIOUS STUDIES and OUR FINDINGS PRESENTED HERE, documenting the LINK between Maternal deficiency of Vitamin D and the INCREASED RISK of Preeclampsia, POINT TO the IMPORTANT ROLE of an appropriate level and adequate Metabolism Of this Vitamin in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 91), ('SUPERFICIAL_RELATIONSHIP', 113), ('IMPORTANT_CONSIDERATION', 167), ('INCOMPLETE_EVIDENCE', 199), ('IMPORTANT_CONSIDERATION', 212), ('SUPERFICIAL_RELATIONSHIP', 222)]	10	[('GO_0007618', 'mating', 126, 'maternal'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 185, 'preeclampsia'), ('GO_0006583', 'melanin biosynthetic process from tyrosine', 264, 'metabolism of ... vitamin'), ('CHEBI_33229', 'vitamin (role)', 283, 'vitamin'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy')]
S131-PMC5487839	PMC5487839	3/2016	S131-PMC5487839	['an increased risk of malformations events has NOT been OBSERVED in Humans (LIMITED DATA) [360]cvitamin dthe ROLE for Vitamin D supplementation in Pregnancy is CONTROVERSIAL, BUT there is NO EVIDENCE of a reduction in adverse Pregnancy outcomes (e.g., Preeclampsia, Stillbirth, neonatal death) [361] or improvement in bone Mineral content in children in studies in which supplementation was given INDEPENDENTLY from Blood levels [362].']	[('FULL_UNKNOWN', 46), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 396)]	7	[('NCBITaxon_9606', 'Homo sapiens', 67, 'humans'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 251, 'preeclampsia'), ('GO_0001966', 'thigmotaxis', 265, 'stillbirth'), ('CHEBI_46662', 'mineral', 322, 'mineral'), ('UBERON_0000178', 'blood', 415, 'blood')]
S25-PMC5634602	PMC5634602	10/2017	S25-PMC5634602	['*formula Fed infants taking <1 liter of formula2008[5]aap—committee on nutrition preterm infants vlbw200–400 iu>50 nmol/l (targeting bone health)discharge Vitamin D RECOMMENDED for breastfed infants 400 iu, for formula Fed 200–400 iu2013[6]aap—committee on nutrition preterm infants>1500g400–1000 iu>50 nmol/l (targeting bone health)tolerating full enteral feeds2013[6]world health organization Preterm infants400–1000 iulow and middle-income countrieswho[7]institute of medicine infants 0–6 months400 iu>50 nmol/l (targeting bone health)under assumption of minimal sunlight2011[8]esphagan preterm infants800–1000 iu>80 nmol/lstable Growing, 1000 to 1800 grams2010[4]pediatric Endocrine society breastfed infants, or those taking <1lformula/day400 iu>50 nmol/l (desire ADDITIONAL STUDIES to determine IF >80 nmol/l is OPTIMAL)800 iu for high risk populations i.e.']	[('FUTURE_WORK', 165), ('FUTURE_WORK', 769), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 801), ('IMPORTANT_CONSIDERATION', 818)]	4	[('GO_0007631', 'feeding behavior', 9, 'fed'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007631', 'feeding behavior', 219, 'fed'), ('GO_0007128', 'meiotic prophase I', 395, 'Preterm'), ('GO_0001947', 'heart looping', 633, 'Growing'), ('UBERON_0005063', 'left ventricular compact myocardium', 677, 'Endocrine')]
S109-PMC5638722	PMC5638722	8/2017	S109-PMC5638722	['the results of our study REVEALED no difference in the incidence of Preeclampsia when the infants are grouped according to their Cord-Blood Vitamin D levels.']	[('INCOMPLETE_EVIDENCE', 25)]	1	[('GO_0007128', 'meiotic prophase I', 68, 'preeclampsia'), ('UBERON_0002240', 'spinal cord', 129, 'cord'), ('UBERON_0000178', 'blood', 134, 'blood'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D')]
S76-PMC5682869	PMC5682869	11/2017	S76-PMC5682869	['EARLY STUDIES concerning Vitamin D in Pregnancy SHOWED an ASSOCIATION with Preeclampsia and caesarean section but also Glucose tolerance, abnormal foetal Grown pattern, Preterm Birth and Reproductive failure.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 58)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 75, 'preeclampsia'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('GO_0040007', 'growth', 154, 'grown'), ('GO_0007565', 'female pregnancy', 169, 'preterm'), ('GO_0007567', 'parturition', 177, 'birth'), ('GO_0000003', 'reproduction', 187, 'reproductive')]
S98-PMC5706533	PMC5706533	11/2017	S98-PMC5706533	['caption (table-wrap): table 2\n\npooled risk ratios from primary meta-analyses of EFFECTS of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrials reporting eligible outcometrials included*intervention-control comparisons included*participants included*risk ratio (95% ci)i2(%) maternal pre-eclampsia3337061.09 (0.43 to 2.76)67†Gestational hypertension2225641.69 (0.73 to 3.92)0gestational diabetes55510300.65 (0.39 to 1.08)45stillbirth16161946060.75 (0.51 to 1.13)0caesarean section17161832401.02 (0.93 to 1.12)0preterm labor4447760.52 (0.26 to 1.05)51hypercalcaemia4111753.11 (0.87 to 11.08)—hypercalciuria2111603.00 (0.12 to 72.56)—hypocalcaemia2112000.05†(0.01 to 0.18)—admission to hospital55517760.97 (0.69 to 1.35)0 neonatal/infant Preterm Birth14131537571.00 (0.77 to 1.30)0low Birth weight87711560.74 (0.47 to 1.16)47small for Gestational age5577410.60†(0.40 to 0.90)0congenital malformations54425090.93 (0.61 to 1.42)0neonatal death53412020.48 (0.16 to 1.49)0.0hypercalcaemia111730.97 (0.31 to 3.08)—hypocalcaemia2111260.10 (0.01 to 1.83)—admission to Neonatal Intensive Care unit55619970.92 (0.66 to 1.28)21respiratory infections (general)1122230.97 (0.77 to 1.23)0upper Respiratory Tract infections2243890.91 (0.77 to 1.06)0lower Respiratory Tract infections44617690.97 (0.84 to 1.12)0asthma or recurrent/persistent wheeze by age 3 years22213870.81†(0.67 to 0.98)0\n*intervention-control group comparisons with zero events in both groups excluded from primary meta-analyses.']	[('SUPERFICIAL_RELATIONSHIP', 80)]	1	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007565', 'female pregnancy', 370, 'Gestational'), ('GO_0007128', 'meiotic prophase I', 781, 'Preterm'), ('GO_0043174', 'nucleoside salvage', 789, 'birth14131537571'), ('GO_0007567', 'parturition', 828, 'birth'), ('GO_0007565', 'female pregnancy', 878, 'gestational'), ('UBERON_0001759', 'vagus nerve', 1104, 'neonatal'), ('UBERON_0001007', 'digestive system', 1113, 'intensive care'), ('UBERON_0000065', 'respiratory tract', 1224, 'respiratory tract'), ('UBERON_0000065', 'respiratory tract', 1284, 'respiratory tract')]
S19-PMC5812027	PMC5812027	2/2018	S19-PMC5812027	['we have PREVIOUSLY SHOWN that higher Vitamin D status in late Pregnancy and larger increase in Vitamin D status during Pregnancy is ASSOCIATED with lower risk of Preeclampsia [3].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 132)]	2	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 162, 'preeclampsia')]
S17-PMC5827025	PMC5827025	2/2018	S17-PMC5827025	['IN CONTRAST, the reports from randomized controlled trials INDICATE that Gestational Vitamin D supplementation CAN markedly decrease Pregnancy COMPLICATIONS including Preeclampsia and Pregnancy induced hypertension11.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 111), ('PROBLEM_COMPLICATION', 143)]	4	[('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
S102-PMC5827025	PMC5827025	2/2018	S102-PMC5827025	['the INCONSISTENCY of PAST FINDINGS MAY BE RELATED to following REASONS: first, cohort among Pregnant women with relatively Vitamin D replete, with a history of Preterm Delivery or at high risk for Preeclampsia; second, Gestational Vitamin D status is a LINK to ethnic DISPARITIES in adverse Birth outcomes24.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 42), ('PROBABLE_UNDERSTANDING', 63), ('SUPERFICIAL_RELATIONSHIP', 253), ('IMPORTANT_CONSIDERATION', 268)]	9	[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'preterm'), ('GO_0007567', 'parturition', 168, 'delivery'), ('GO_0007128', 'meiotic prophase I', 197, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 219, 'gestational'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('GO_0007567', 'parturition', 291, 'birth')]
S554-PMC5941617	PMC5941617	5/2018	S554-PMC5941617	['supplementing Pregnant women with Vitamin D in a single or continued dose increases Serum 25(Oh)D at term and MAY reduce the RISK of Preeclampsia, low Birth weight and Preterm Birth.']	[('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 125)]	2	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 84, 'serum'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 93, 'OH ... D'), ('GO_0007128', 'meiotic prophase I', 133, 'preeclampsia'), ('GO_0007567', 'parturition', 151, 'birth'), ('GO_0007565', 'female pregnancy', 168, 'preterm'), ('GO_0007567', 'parturition', 176, 'birth')]
S13-PMC6011374	PMC6011374	6/2018	S13-PMC6011374	['evidence SUGGESTS that Vitamin D deficiency is ASSOCIATED with a number of Pregnancy COMPLICATIONS including Preeclampsia (pe), Gestational diabetes mellitus (gdm) and spontaneous Preterm Birth (Sptb) [2–4].']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 47), ('PROBLEM_COMPLICATION', 85)]	3	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 109, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 128, 'gestational'), ('GO_0007565', 'female pregnancy', 180, 'preterm birth'), ('PR_000015390', 'sterol O-acyltransferase 2', 195, 'sPTB')]
S80-PMC6011374	PMC6011374	6/2018	S80-PMC6011374	['caption (table-wrap): table 2\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaneous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status categorised based on standardised quartiles and clinical definitions of Vitamin D statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)Vitamin d status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that Serum was sampled based as previously described [34]\n†reference category\n\nSerum 25(Oh)D, Pregnancy outcome and fetal sex\nas THERE IS EVIDENCE to SUGGEST that Vitamin D Metabolism within the Placenta MAY DIFFER with respect to fetal sex [35] THUS, we ASSESSED the EFFECT of “standardised” Vitamin D status on Pregnancy outcome stratified by fetal sex (table\xa03).']	[('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2251), ('INCOMPLETE_EVIDENCE', 2305), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2309), ('PROBABLE_UNDERSTANDING', 2347), ('QUESTION_ANSWERED_BY_THIS_WORK', 2356), ('SUPERFICIAL_RELATIONSHIP', 2369)]	7	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 210, 'preterm birth'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 1141, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1882, 'gestation'), ('CHEBI_30879', 'alcohol', 1906, 'alcohol'), ('UBERON_0001977', 'blood serum', 2060, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2066, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2066, '25(OH)D'), ('UBERON_0001977', 'blood serum', 2106, 'serum'), ('UBERON_0001977', 'blood serum', 2180, 'Serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 2189, 'OH)D'), ('GO_0007565', 'female pregnancy', 2195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2264, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 2264, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 2296, 'placenta'), ('CHEBI_27300', 'vitamin D', 2394, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2414, 'pregnancy')]
S86-PMC6011374	PMC6011374	6/2018	S86-PMC6011374	['caption (table-wrap): table 3\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sexpregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci)standardised quartiles**males\u2003low367 (26)173 (47)1.00 (0.85, 1.18)24 (7)1.24 (0.65, 2.34)31 (8)1.11 (0.64, 1.94)18 (5)1.25 (0.58, 2.68)22 (6)1.09 (0.60, 1.98)43 (12)1.14 (0.73, 1.79)\u2003low-moderate364 (26)163 (45)1.01 (0.86, 1.19))20 (5)1.11 (0.58, 2.12)32 (9)1.25 (0.73, 2.13)13 (4)1.06 (0.48, 2.38)18 (5)0.93 (0.49, 1.76)45 (12)1.23 (0.80, 1.88)\u2003moderate-high359 (25)152 (42)1.0†16 (4)1.0†23 (6)1.0†11 (3)1.0†18 (5)1.0†35 (10)1.0†\u2003high325 (23)111 (34)0.86 (0.71, 1.04)15 (5)1.18 (0.59, 2.36)17 (5)0.90 (0.50, 1.62)4 (1)0.45 (0.15, 1.38)15 (5)0.97 (0.50, 1.88)26 (8)0.77 (0.47, 1.26)females\u2003low380 (28)169 (44)0.91 (0.77, 1.06)23 (6)0.85 (0.47, 1.55)30 (8)0.87 (0.52, 1.45)13 (3)0.51 (0.25, 1.04)14 (4)0.61 (0.31, 1.18)45 (12)0.88 (0.58, 1.35)\u2003low-moderate353 (26)168 (48)0.99 (0.85, 1.15)24 (7)1.03 (0.57, 1.85)31 (9)0.92 (0.57, 1.50)9 (3) 0.44(0.20, 0.97) 18 (5)0.79 (0.43, 1.45)33 (9)0.74 (0.48, 1.13)\u2003moderate-high334 (24)149 (45)1.0†19 (6)1.0†28 (8)1.0†17 (5)1.0†21 (6)1.0†31 (9)1.0†\u2003high314 (23)128 (41)1.00 (0.84, 1.19)19 (6)1.29 (0.70, 2.35)20 (6)0.85 (0.49, 1.46)6 (2)0.48 (0.19, 1.23)12 (4)0.60 (0.30, 1.21)29 (9)0.82 (0.53, 1.28)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that serum was sampled based as previously described [34]\n†reference category\n\ndiscussion\nthis study ADDS TO THE current body of LITERATURE on Vitamin D status in a population of Pregnant australian and new zealand women and provides INSIGHT into normal circulating levels of 25(Oh)D in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2125), ('INCOMPLETE_EVIDENCE', 2258)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 209, 'preterm birth'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1805, 'gestation'), ('CHEBI_30879', 'alcohol', 1829, 'alcohol'), ('UBERON_0001977', 'blood serum', 1983, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1989, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1989, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2203, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2300, '25(OH)D'), ('GO_0007565', 'female pregnancy', 2317, 'pregnancy')]
